Tamoxifen and Amphetamine Abuse: Are There Therapeutic Possibilities?
Overview
Chemistry
Neurology
Affiliations
Although best known as a selective estrogen receptor modulator (SERM), tamoxifen is a drug with a wide range of activities. Tamoxifen has demonstrated some efficacy has a therapeutic for bipolar mania and is believed to exert these effects through inhibition of protein kinase C (PKC). As the symptoms of amphetamine treatment in rodents are believed to mimic the symptoms of a manic episode, many of the preclinical studies for this indication have demonstrated that tamoxifen inhibits amphetamine action. The amphetamine-induced increase in extracellular dopamine which gives rise to the 'manic' effects is due to interaction of amphetamine with the dopamine transporter. We and others have demonstrated that PKC reduces amphetamine-induced reverse transport through the dopamine transporter. In this review, we will outline the actions of tamoxifen as a SERM and further detail another known action of tamoxifen-inhibition of PKC. We will summarize the literature showing how tamoxifen affects amphetamine action. Finally, we will present our hypothesis that tamoxifen, or an analog, could be used therapeutically to reduce amphetamine abuse in addition to treating mania.
Potential of covalently linked tamoxifen hybrids for cancer treatment: recent update.
Shagufta , Ahmad I, Nelson D, Hussain M, Nasar N RSC Med Chem. 2024; 15(6):1877-1898.
PMID: 38911170 PMC: 11187546. DOI: 10.1039/d3md00632h.
Real-World Long-Term Experience on Endoxifen in Bipolar Disorder with Psychotic Symptoms.
Thanvi V Case Rep Psychiatry. 2022; 2022:3684181.
PMID: 35818415 PMC: 9271003. DOI: 10.1155/2022/3684181.
Neuropsychiatric effects of tamoxifen: Challenges and opportunities.
Novick A, Scott A, Epperson C, Schneck C Front Neuroendocrinol. 2020; 59:100869.
PMID: 32822707 PMC: 7669724. DOI: 10.1016/j.yfrne.2020.100869.
Massadeh S, Omer M, Alterawi A, Ali R, Alanazi F, Almutairi F Pharmaceutics. 2020; 12(7).
PMID: 32679809 PMC: 7408428. DOI: 10.3390/pharmaceutics12070666.
Yoest K, Cummings J, Becker J Br J Pharmacol. 2018; 176(21):4136-4148.
PMID: 30381823 PMC: 6877897. DOI: 10.1111/bph.14531.